Morphotek Signs Collaboration Agreement With Synageva
Morphotek has signed a research collaboration agreement with Synageva to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.